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Abstract: Trypanosoma brucei (T. brucei) is the agent of Human 
African Trypanosomiasis (HAT), a neglected disease that threats the 
life of 65 million people in sub Saharan Africa every year. 
Unfortunately, available therapy is unsatisfactory, mainly due to safety 
issues and developing resistances. Significant efforts over the last 
decades have been made in the discovery of new potential agents 
from the World Health Organization and public–private partnership 
organizations such as the Drugs for Neglected Diseases Initiative 
(DNDi). Whereas antifolates have been a precious source of drugs 
against bacterial infections and malaria, no effective molecules 
towards T. brucei have been identified so far. Considering the simple 
T. brucei folate metabolism, and the results obtained up to now in this 
research field, we believe that further investigation might lead to 
effective chemotherapeutic agents. We present herein a selected 
collection of the more promising results obtained so far in this field, 
underlining the opportunities that could lead to successful therapeutic 
approaches in the future. 
1. Introduction 
Trypanosoma brucei (T. brucei) is a protozoa of the 
Trypanosomatidae family which causes the Human African 
Trypanosomias (HAT). The disease is spread in the sub Saharan 
Africa where it threats the life of 65 million people although only 
2,804 new cases have been reported in 2015, and less than 
20,000 were estimated.[1] The parasites enter in the human body 
through the bites of Glossina spp flies (tsetse flies). The first 
hemolymphatic phase of the disease is characterized by 
unspecific symptoms like local edema, intermittent fever, and 
headache. When the parasite penetrates the central nervous 
system (neuronal phase), more characteristic symptoms such as 
sleep-rest cycle alterations, mood disturbs, and lethargy, appear. 
The last stage of the infection leads to the death of the human 
host without an appropriate pharmacologic intervention. Two 
forms of the disease are described: the eastern HAT (r-HAT), 
caused by T. brucei rhodesiense, spread in eastern and southern 
Africa, and the western HAT (g-HAT), caused by the subspecies 
T. brucei gambiense, mainly occurring in western and central 
Africa. The first form rapidly evolves to the neurological phase and, 
because of this, is often referred to as the acute and lethal HAT 
(it indeed represents less than 2% of the total cases).[1a, 2] A third 
subspecies, T. b. brucei, is not normally infective to humans and 
is often used to perform in vitro experiments. 
Since a vaccine is not available,[1b] the treatment of the disease is 
based on diagnosis (with better outcomes for earlier diagnosis) 
and treatment with the few old drugs approved for this application 
(fig. 1).[3] Among them, pentamidine and suramine are indicated 
for the first stage of g-HAT and r-HAT, respectively. To treat 
second stage HAT, drugs should be able to cross the blood-brain 
barrier (BBB). Currently, melarsoprol, an organ-arsenic 
compound, remains the first choice for the first-line treatment of 
second stage r-HAT, whereas the nifurtimox-eflornitine 
combination therapy (NECT) stands as the most promising first-
line treatment for second-stage T. b. gambiense HAT. Compared 
with eflornithine monotherapy, NECT is preferred for a synergistic 
effect of the two drugs and for an easier administration regimen.[1b, 
4] These agents are far from ideal, presenting many shortcomings, 
such as high cost, poor selectivity, toxicity, emergence of 
resistance, and they often require hospitalization for their 
administration.[5] Moreover, some of these drugs show serious 
toxicity issues, as happens with melarsoprol, which causes highly 
lethal (10-70% of the cases) reactive encephalopathy to the 5-
18% of treated patients.[1b] Recently, fexinidazole (fig. 2) has 
successfully completed a phase II/III clinical trial, showing 
comparable efficacy and safety to the NECT during the treatment 
of g-HAT. If approved and registered, fexinidazole would 
represent the first new chemical entity for the disease since the 
early 1980s and could become the drug of choice for the 
treatment of the disease, also considering its favorable 
therapeutic scheme (single daily oral dose).[6] 
Figure 1. Drugs approved for the treatment of I stage (i.e., suramin, 
pentamidine) and II stage (i.e., melarsoprol, eflornithine, nifurtimox) of HAT. 
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Figure 2. Agents under clinical evaluation for HAT. Fexinidazole successfully 
completed phase II/III studies, whereas acoziborole is still under phase II/III 
clinical trial. 
Another molecule, acoziborole (or SCYX-7158, fig. 2), is currently 
under phase II/III clinical trial for the treatment of second stage g-
HAT.[7] Although current cases are relatively few, attention to the 
disease should be keep high, since resurgence of the disease has 
been already occurred in the past.[2a] For this reason, it is 
important to continue the research for novel chemotherapeutic 
agents. Folate pathway has been a precious source of 
pharmaceutical targets for the treatment of cancer and microbial 
infections (examples of antifolate drugs are reported in fig. 3).[8] 
Despite this, no effective antifolate compounds have been 
described for the treatment of HAT, and this route has just been 
initially explored in T. brucei from a pharmacological point of view. 
We present herein a selected collection of the more promising 
results obtained so far in this research field, underlining the 
opportunities that, in our opinion, could lead to successful 
therapeutic approaches in the future. 
Figure 3. Antifolate drugs currently used in therapy. 
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1.1. The Trypanosoma brucei folate pathway 
Folate metabolism in human has been exhaustively described.[9] 
It consists of several, often redundant, interconnected paths that 
lead to different modifications of folate and its derivatives. 
Tetrahydrofolate (THF), reduced form of folate, represents its 
functional state. All the other modifications have, in ultimate, the 
same scope: link a monocarbon unit to the nitrogen 5 and/or 10 
of THF. These “charged” folates serve as donors of C1 units in the 
synthesis of purines, pyrimidines and amino acids. 
The biochemical routes that stand behind the folates reduction 
and functionalization in T. brucei (scheme 1) are far simpler 
compared to the human ones. T. brucei is folate auxotroph, so it 
has to salvage it from the environment. Putative folate 
transporters have been recently identified, together with a 
putative folylpolyglutamyl synthetase (FPGS).[10] The parasite, 
differently from humans, expresses a fused dihydrofolate 
reductase-thymidylate synthase (DHFR-TS) and an enzyme, the 
pteridine reductase-1 (PTR1, absent in humans), that are able to 
reduce folates. Basing on the up-to-date knowledge, THF can be 
converted in only two active forms, N5,N10-
methylenetetrahydrofolate (N5,N10-CH2-THF) and N10-
formyltetrahydrofolate (N10-CHO-THF), cofactors for the 
synthesis of deoxythimidylate monophosphate (dTMP) and of 
formylmethionyl-tRNAMet (fMet-tRNAMet), respectively. T. brucei 
can also uptake N5-methyltetrahydrofolate (N5-CH3-THF, the 
major circulating form of THF in the human body) that can be used 
as a cofactor for the synthesis of methionine (Met) from 
homocysteine (hCys), catalyzed by methionine synthase (MS).[11] 
Considering the simplicity of the pathway and the historical impact 
of antifolates as chemotherapeutics, a deep characterization of 
the enzymes involved in the folate pathway could be useful to 
accelerate the drug discovery process towards novel, more 
selective and affordable inhibitors. In the following paragraphs, 
we collected some significant results presented in literature 
targeting the T. brucei folate metabolism. 
2. Enzyme involved in reductive metabolism 
A fused DHFR-TS enzyme (EC 1.5.1.3-2.1.1.45) is the mayor 
responsible for the reduction of DHF to the active reduced form 
THF with the concomitant consumption of NADPH. Currently 
available DHFR inhibitors did not show a notable antiproliferative 
activity. This result could be mainly attributed to the presence in 
T. brucei of PTR1, which offers an alternative metabolic route for 
the generation of THF, in addition to its ability to reduce folate to 
DHF.  
2.1. Dihydrofolate reductase 
Sienkiewicz et al. validated TbDHFR as a target on its own.[12] Its 
activity turned out to be essential for viability and virulence of the 
parasite, but considerable effects were only observed when the 
inhibition was complete (as in double knock-out cell lines). The 
authors also underlined that PTR1 is unable to compensate 
DHFR deficiency. The crystal structure of the DHFR domain has 
been solved by Vanichtanankul et al. (PDB: 3RG9): it folds in 
different secondary structures organized in a C- and N-terminal 
domains separated by a cleft in which are located the binding sites 
for substrate and NADPH.[13] The enzyme is quite similar to the 
isoforms of other parasites (58% and 46% of sequence identity 
with Trypanosoma cruzi and Leishmania major, respectively), but 
it presents important differences with the human one (only 26% of 
sequence identity).[14] 
 
 
 
 
 
Scheme 1. Folate pathway in T. brucei (left) and structures of folates (right). Folate is collected from the environment. A putative FGPS[10] converts it in polyglutamyl 
folate (PGF), the cellular pool of folate. DHFR and PTR1 participate to the reduction of folate to THF (only PTR1 can reduce folate to DHF). This last is converted 
by the glycine cleavage system (GCS) in N5,N10-CH2-THF, the cofactor for the synthesis of dTMP. DHCH (N5,N10-CH2-THF dehydrogenase/cyclohydrolase) converts 
N5,N10-CH2-THF into N10-CHO-THF, used as cofactor for the synthesis of fMet-tRNAMet, catalyzed by the formyl methionyl transferase (FMT). N5-CH3-THF is acquired 
from the human host and converted in THF thanks to the action of the MS, which converts hCys into Met.
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Figure 4. Binding modes of DHF (white) in hDHFR and TbbDHFR (rose). 
NAPDH is represented in light blue. Reproduced from Sharma et al.[15] 
Some relevant variations are located in the folate binding site, and, 
in particular, are: a) a small tunnel is present under the pteridine 
ring in TbDHFR; b) residues Gly20-Asp21 of hDHFR, overall 
negatively charged, occupy the channel between the substrate 
and the NADPH binding pocket, while in T. brucei the neutral 
residues Gly45-Thr46 are found in the same positions; c) while in 
hDHFR Phe31 points towards the benzamide moiety of the 
substrate, in TbDHR we find Met55, resulting in a larger binding 
pocket in the parasitic enzyme; d) the positions occupied by Gln35 
and Asn69 in the human enzyme, are occupied by Arg39 and 
Phe94, respectively, in TbDHFR. The two binding modes are 
shown in figure 4. Phe94 is also oriented towards Met55, 
preventing the interaction between the glutamate tail of the ligand 
and Arg95.[14-15] The presence of Thr86 in the active site makes 
TbDHFR less sensitive towards rigid classical antifolates, as PYR 
(Ki 24 nM) and CYC (Ki 256 nM), rather than more flexible 
compounds, as WR99210 (Ki 1.1 nM, fig. 5). 
 
 
 
 
Figure 5. Structure of WR99210. 
Diaminopyrimidines and diaminoquinazolines 
The first groups of inhibitors have been developed starting from a 
known 5-benzyl-2,4-diaminopyrimidine inhibitor (1) of LmDHFR, 
which presented interesting inhibitory activity and remarkable 
selectivity.[16] Starting from the model compound 1, Chowdhury et 
al. developed a series of analogues in which they introduced 
modification at 3’, 4’ and 6 positions.[17] The diaminopyrimidine 
ring of these compounds binds into the active site establishing a 
salt bridge with Asp54, while the group in the 3’ position is 
important for the selectivity, interacting with Phe94 of TbDHFR, 
while in the human isoform the same position is occupied by 
Asn69. The peak of activity and selectivity (table 1) has been 
obtained with derivatives characterized by a linear alkoxy chain in 
position 3’ (2, 3 and 4), with a chain length up to 6 carbon units, 
and alkoxy chain in 4’ (6). Compounds with branched alkoxy 
chains in 3’ also possess interesting activity (5), while longer 
chains decrease the selectivity of the inhibitors.  
Table 1. Enzyme inhibition and in vitro activities for the diaminopyrimidine 
compounds. 
 
 
Compd R1 R2 TbDHFR 
Ki (nM)] 
T. brucei 
rhodesiense 
IC50 (μM) 
L6-cells[b] 
MIC or IC50 
(μM) 
1 OOct H 24 (100) 2 <34 (MIC) 
2 OEt H 8.6 (184) 21 >410 (MIC) 
3 OBu H 3.6 (257) 5 121 (MIC) 
4 OPent H 7.1 (154) 4 115 (MIC) 
5 OiPr H 8.8 (156) 14 >388 (MIC) 
6 H OPr 6.4 (442) 10 388 (MIC) 
7 OH OOct n.d. 0.73 14.0 (IC50) 
8 OHex OHex n.d. 0.77 5.5 (IC50) 
TMP / / 10 (134) 148 n.d. 
PYR / / 11 (11) 7 n.d. 
[a] When determined, the selectivity index (hDHFR Ki/TbDHFR Ki) is reported 
in brackets. [b] Rat skeletal myoblast cell line. N.d.: not determined. 
 
Some compounds also showed in vitro activity on T. b. 
rhodesiense cultures, generally in the micromolar range, with a 
selective toxicity towards the parasite. However, especially for the 
3’-substituted analogues, there is not a clear correlation between 
the range of enzyme inhibition and in vitro growth inhibition. Since 
the most active compounds possess longer alkyl chain, this effect 
might be due to an improved rate of cell penetration. Some 
compounds, such as 1, also prolonged the life span of mice 
infected by T. brucei. Additional 4’-alkyloxy- and 3’,4’-dialkyloxy- 
substituted analogues were described by the same group.[18] The 
inhibitory activity of these compounds was determined against 
LmDHFR and TcDHFR. In vitro activities were generally 
comparable with the ones of the first series of diaminopyrimidines 
but these compounds showed a modest selectivity. Actually, it is 
difficult to extrapolate a clear trend in activity for this set of 
compounds due to the low range in the in vitro activity, which, in 
addition, is likely affected by their different physicochemical 
properties. The 2,4-diaminoquinazoline scaffold appeared to be 
promising for the design of parasitic DHFR inhibitors.[19] 
Khabnadideh et al. linked, with a two-carbon atom chain, this 
heterocycle to a substituted phenyl ring, essential to generate 
selectivity.[20] These compounds (table 2) showed good inhibitory 
activity towards LmDHFR and interesting trypanocidal activity 
(from 0.67 to 0.054 μM), but only modest selectivity between 
parasitic and mammalian cells (4-16 folds). 
hDHFR TbbDHFR 
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Table 2. In vitro activities of the diaminoquinazoline compounds. 
 
 
Compd] R T. b. rhodesiense 
IC50 (μM) 
L6-cells[a] IC50 (μM) 
9 H 0.054 0.82 
10 Et 0.081 0.84 
11 Hex 0.095 1.5 
12 Bn 0.10 1.2 
[a] Rat skeletal myoblast cell line. 
 
The alkylation of the phenolic OH always showed a detrimental 
effect on the IC50 profile, but to a lesser extent in the case of ethyl, 
hexyl and benzyl substituents. Compounds with a flexible linker 
(ethyl-) are generally more potent than the ones with a rigid linker 
(ethenyl-/ethynyl-), in accordance with the findings of 
Vanichtanankul et al.[13] 
 
Benzoazepinones and benzodiazepines 
Zuccotto and co-workers[21] identified TcDHFR inhibitors 
characterized by a benzoazepin-2-one (13) or a benzo-1,4-
diazepine structure (19). A series of derivatives with these two 
scaffolds were synthesized and assayed for their growth inhibitory 
activity on T. brucei (table 3 and 4) showing good potencies and 
a selectivity in the range from modest to good.[21] 
2.2. Pteridine reductase 1 (PTR1) 
PTR1 (EC 1.5.1.33) is a member of the short-chain 
dehydrogenase/reductase family (SDR) able to catalyze the 
reduction of both folate, biopterine, and their dihydro forms, i.e., 
DHF and dihydrobiopterine (DHB), with consumption of NADPH. 
TbPTR1 has been genetically validated as a target: the lack of the 
enzyme has cytocidal effects together with phenotypic defects, 
and reduced in vivo virulence. The reduction of the 
tetrahydrobiopterine (THB) pool seems to be the explanation of 
these results but the still lacking knowledge of pterines functions 
in T. brucei prevents any clear conclusion.[22] Each monomer of 
the active asymmetric tetramer presents two α-/β-domains in 
which seven β-sheets are between two sets of α-helices. The 
active site is an L-shaped depression mainly formed by a single 
subunit, but one of its end is created by the C-terminus of a 
partner subunit. The cofactor and Phe97 contribute to the 
formation of the catalytic center. The pterine ring of 
substrates/products is indeed sandwiched between NADPH 
nicotinamide and Phe97. Other key interactions are established 
between the polar groups of the ligand, NADPH, and active site 
residues (fig. 6b). TbPTR1 possesses a closer binding site, in 
comparison to LmPTR1, caused by a less flexible β-6/α-6 loop.  
Table 3. In vitro activities of benzoazepin-2-one compounds. 
 
 
 
 
Compd R1 R2 T.b.rhodesiense 
IC50 (μM) 
L6-cells[a] 
MIC (μM) 
13 (R)-Bn (R)-4-MeO-Ph 3.6 >163 
14 (R)-OAc (S)-4-MeO-Ph 4.2 180 
15 (R)-Me (R)-4-MeO-Ph 1.6 56 
16 (S)-Me (R)-4-HO-Ph 2.2 68 
17 (S)-OAc (R)-4-MeO-Ph 2.9 60 
18 / / 1.5 66 
[a] Rat skeletal myoblast cell line. 
Table 4. In vitro activities of benzodiazepines 19-22. 
Compd R T. brucei 
rhodesiense IC50 (μM) 
L6-cells[a] 
MIC (μM) 
19 p-SPh 1.0 >166 
20 o-SPh 3.5 150 
21 p-SCy 2.2 >16 
22 m-SPh 3.2 >48 
[a] Rat skeletal myoblast cell line. 
 
In the case of folates, the pABA and the glutamate residue are 
directed out of the active site. Vice versa, MTX binds PTR1 with 
the pterine ring rotated by 180° compared to the orientation of 
folate (fig. 6a): in this way, the N8 interacts with Arg14 and with 
the pyrophosphate through a water bridge while the 4-NH2 
interacts through an hydrogen bond with Tyr 174.[23] 
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Figure 6. TbPTR1 in complex with MTX (a) and folate (b) and NADPH cofactor. 
Reproduced from Tulloch et al.[23] 
Pyrimidines and related heterocycles 
Three different scaffolds (A-C, fig. 7) were assessed for their 
ability to inhibit the enzyme.[23] 2,6-Diaminopyrimidines (scaffold 
A) showed only a weak inhibition for TbPTR1 when group R is an 
amino or an N-cyclopropylamino group (Ki > 35 μM). The activity 
is increased when R is an alkylthio group, with the most potent 
compound (24) showing a Ki of 3.2 μM. The introduction of a p-
methoxy group on the benzyl ring of compound 24 reduced the 
activity for both the enzymes by a factor of ten. Pteridines 
(scaffold B) showed a good inhibitory activity for the enzyme, but 
their activity is higher against LmPTR1 (aggiungi I dati qui). On 
the other hand, pyrrolopyrimidines (scaffold C) showed a 
preference for TbPTR1 and a promising activity, with Ki in the 
micromolar or submicromolar range.[23,24] A series of analogues, 
characterized by the C core, were synthesized in an extensive 
study that led to a complete structure-activity relationships study 
(Table 5).[24] The substitution of the 4-O with an amino group was 
found favorable in some cases, but the most important remark is 
the need of a bulky hydrophobic substituent on the pyrrole ring, 
with the most interesting compounds bearing two phenyl rings in 
the 5 and 6 positions. Improvements in activity were obtained with 
the introduction of an halogen atom in the para or meta position 
of the aryl groups appended in position 5 or 6, while other 
modifications, such as the alkylation of the heteroatom at 4 
position, the introduction of branched alkyl groups or a sulfone 
group on the aromatic rings, caused a loss of activity or worsen 
the solubility properties of the compounds, especially for the 4-
oxo series. Crystal structures of the complexes inhibitor-NADPH-
TbPTR1 were generated, showing that most of the compounds 
bind the enzyme with a substrate-like pose. 
 
Figure 7. Selected examples of TbPTR1 inhibitors characterized by scaffolds 
A-C. The relative Ki are reported in brackets. 
Notably, it was also observed that compounds bearing a formyl 
group on the phenyl ring at position 6 establish a thioester linkage 
with Cys168 (probably arising from an initial thioacetal 
intermediate), suggesting the opportunity for the design of 
covalent inhibitors.[25] Six compounds (31-36, table 5) with 
improved pharmaceutical properties were selected for in vivo 
evaluation in mice. At the selected dose of 30 mg/kg, compound 
32 did not show curative effects while compound 31 induced 
chronic toxicity. The other compounds were tolerated up to 4 days 
when administered once daily and reduction of parasitaemia from 
108 to below detection limits was demonstrated. Mice survived 
after treatment with compounds 34 and 35, but unfortunately, 
showed a relapse of parasitaemia on day 10.[24]  
 
Aminobenzimidazoles 
5-Chloro-aminobenzimidazole 37 emerged as an interesting 
inhibitor of TbPTR1 (Kiapp 10.6 μM) from a research campaign 
focused on compounds characterized by a non-classical scaffold 
(not related to folate and known antifolates) and by favorable 
pharmaceutical properties.[26] The substitution of the N1 of 
aminobenzimidazole with a benzyl group (compound 38) was not 
detrimental (Kiapp 16 μM). In contrast, when the benzyl group was 
linked to the 2-amino group a drastic drop in activity was observed. 
Optimization of the substituents on the phenyl ring led to 
compound 39 (Kiapp 0.4 μM), which was further modified at the 4 
or 7 positions: position 4 tolerates only small substituents, while 
position 7 can be decorated with bulkier groups, such as a phenyl 
ring as in compound 40, the most potent inhibitor of TbPTR1 
described so far (Kiapp 0.007 μM).[27] The structures of 
benzimidazole inhibitors are reported in figure 8. 
 
Figure 8. Structures of TbPTR1 aminobenzimidazole inhibitors. 
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Table 5. Biological data for pyrrolopyrimidines 31-36. 
 
 
Compd R1 R2 R3 TbPTR1 Kiapp(μM)[a] T.b.rhodesiense IC50 (μM) HEK[b] IC50 (μM) 
31 OH Ph p-Br-Ph 0.230 7.38 (HMI-9), 3.20 (CMM) >100 
32 OH Ph(CH2)2 Ph 0.95 0.40 (HMI-9), 0.14 (CMM) 33.18 
33 NH2 Ph p-F-Ph 0.24 0.32 (HMI-9), 0.08 (CMM) 49.19 
34 NH2 p-MeO-Ph p-F-Ph 0.58 0.27 (HMI-9), 0.083 (CMM) 39.14 
35 NH2 Ph p-Br-Ph 0.135 0.97 (HMI-9), 0.25 (CMM) 39.63 
36 NH2 m-Cl-Ph p-F-Ph 0.29 0.39 (HMI-9), 0.19 (CMM) 34.59 
[a] The Kiapp is the apparent Ki before correction for the inhibition modality-specific influence of substrate concentration relative to Km. Ki can be derived from the 
equation Kiapp = Ki / (1 + S ∙ Km-1), where S and Km refers to the pterine substrate. [b] HEK: human embryonic kidney cells. HMI-9: Hirumi’s Modified Iscove’s medium 
9. CMM: Creek’s Minimal Medium.
 
Remarkably, X-ray crystallography analysis revealed that the 
binding mode of these inhibitors completely differs from the one 
of folates and MTX. Although compound 37 is locked into the 
catalytic pocket, 38 and 40 are located in a perpendicular area, 
away from the nicotinamide of the cofactor (fig. 9). Amino acidic 
residues that participate to create this pocket are Phe97, Asp161, 
Met163, Cys168, Phe171, Tyr174 and Gly205. The protonated 
N3 and the 2-NH2 group of the ligand form a bidentate interaction 
with the carboxylate moiety of Asp161; the amino group also 
interacts with the backbone carbonyl of Gly205. A second pocket, 
formed by Val206, Trp221, Leu263, Cys168 and Met163, closed 
by His267 and Asp268 of a neighboring subunit, accommodates 
the dichlorophenyl ring of 40. Unfortunately, the high inhibitory 
activity of derivative 40 did not translate in an improved inhibitory 
activity toward T. brucei (EC50 9.9 μM) and some of these 
compounds, unfortunately, showed toxicity toward human cell 
lines. The authors pointed the attention to the low Km/Ki ratio for 
40 (only 10) to explain the observed low in vitro antiproliferative 
activity. The inhibitory activity of this compound should be then 
increased at least of two orders of magnitude to produce an 
effective drug candidate. 
3. Enzymes involved in THF functionalization 
3.1. N5,N10-Methylene-THF 
N5,N10-Methylenetetrahydrofolate is one of the more important 
active form of THF. It functions as a donor of a C1 unit in the 
synthesis of thymidylate (catalyzed by TS). In trypanosomatids, 
the monocarbon unit can be, generally, donated to THF by serine 
or by glycine: the first reaction is catalysed by the PLP-dependent 
Ser hydroxymethyltransferase (SHMT) with release of Gly, while  
 
in the other case the glycine cleavage system (GCS), a tetrameric 
complex, degrades the amino acid to ammonia, CO2 and donate 
the C1 unit to THF.[28] T. brucei completely lacks of any SHMT-
encoding gene, thus the GCS appears to be the only responsible 
for the synthesis of N5,N10-CH2-THF.[29] GCS is a multimeric 
complex formed by three enzymes, proteins P, T and L, and a 
carrier protein, protein H, to which lipoic acid is covalently bound. 
Protein P, also known as glycine dehydrogenase (EC 1.4.4.2), 
decarboxylates glycine and transfers the aminomethyl radical to 
lipoic acid (bound to protein H). Protein T (or aminomethyl 
transferase, EC 2.1.2.10) transfers the C1 unit from lipoic acid to 
tetrahydrofolate converting it to N5,N10-CH2-THF. The reduced 
lipoic acid is oxidized from protein L (or dihydrolipoamide 
dehydrogenase, EC 1.8.1.4) with reduction of NAD+ and a new 
cycle can begin.[30] 
 
Figure 9. Crystallographic binding mode of compound 40. Enzyme is depicted 
in purple, the inhibitor in orange. Reproduced from Mpamhanga et al.[26] 
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Scheme 2. Mechanism of GCS. 
The mechanism is resumed in scheme 2. The structures of some 
of these proteins have been described for some bacteria, such as 
E. coli[31] and T. thermophiles,[32] and, in particular, the structure 
of T. cruzi dihydrolipoamide dehydrogenase has been reported in 
the protein data bank (PDB 2QAE). The role of the same 
component of the GCS has been studied in T. brucei. Both double 
null mutation and silencing of protein L expression by RNAi 
resulted in alterations in the morphology and in the cell cycle 
distribution of the parasites. Moreover, double null mutants were 
not able to cause infection in mice. For the bloodstream form of T. 
brucei (the form present in the human host), these effects have 
been related with GCS activity defects.[33] Despite the evidence of 
the importance of GCS for the parasite, only few information are 
available, especially from a structural point of view. Given the 
central position of GCS in T. brucei folate metabolism, advances 
in this area might prompt the development of new effective agents 
against the parasite. 
3.2. N10-formyl-THF 
In N10-CHO-THF, the C1 unit is present as a formyl group. In 
trypanosomatids, which are auxotrophs for purines, this cofactor 
participates only in the formylation of the methionyl-tRNAMet to 
fMet-tRNAMet (the initiator aminoacyl-tRNA in protein synthesis).  
 
Figure 10. Selected inhibitors of TbDHCH. 
 
While in humans and in other parasites the synthesis of N10-CHO-
THF is catalyzed by different enzymes starting from different 
substrates,[34] in T. brucei only DHCH (or FolD), a bifunctional 
enzyme, catalyzes the biosynthesis of the cofactor.[34a]DHCH is a 
bifunctional enzyme that converts N5,N10-CH2-THF into N10-CHO-
THF in two steps through the formation of N5,N10-methenyl-THF 
(N5,N10-CH+-THF). In the first step (dehydrogenase, DH, EC 
1.5.1.5) a NADP+-dependent oxidation takes place, then N5,N10-
CH+-THF is hydrolyzed by an activated water molecule thanks to 
the cyclohydrolase activity (CH, EC 3.5.4.9). The enzyme has 
been described as essential for Pseudomonas aeruginosa,[35] L. 
major,[34b] and we have recently assessed the T. brucei ortholog 
as potential antiparasitic target.[36] We have described a series of 
compounds derived from compound 41 (Ki 1.1 μM) in which we 
studied the effect of the substitution of the amino acidic tail (fig. 
10). Compound 41 (EC50 49 μM) showed better in vitro selectivity 
than compound 42 (EC50 53 μM), a known inhibitor of DHCH,[37] 
and allowed us to solve the structure of the ternary crystal 41-
NADP+-TbDHCH (fig. 11a). Most of the analogues showed 
micromolar Ki values or, in the case of 43 (Ki 0.48 μM) and 44 (Ki 
0.54 μM), even lower, possibly thanks to the enhanced interaction 
of the amino acid tails of these compounds with the enzyme (as 
predicted by binding studies, fig. 11b and 11c). The same 
compounds were assayed for their trypanocidal activity but, with 
the exception of compound 41, they did not show antiparasitic 
activity, probably due to their unfavorable pharmacokinetic 
properties, such as poor solubility and high hydrophilicity. 
4. Other potential enzymatic targets 
Other underexplored possible approaches in the design of new 
antifolates exist. Although we do not know yet their importance for 
the parasite, FPGS, TS, FMT, and MS could also be interesting 
targets. Surely, data available nowadays are too scarce to invite 
to a drug discovery campaign, but these enzymes, once they will 
be isolated and characterized, could be included in multitarget 
assays. 
4.1. Thymidylate synthase (TS) 
Gibson et al.[11] studied the effect of nolatrexed (NTX), 
pemetrexed (PMX), and raltitrexed (RTX), three known inhibitors 
of hTS, towards TbTS and TbDHFR (table 6). NTX is the most 
potent TbTS inhibitor (Ki 39.4 nM), while the other two are more 
active towards TbDHFR. However, the in vitro activities of RTX 
and PMX are higher, probably due to the activity of FPGS 
(polyglutamyl derivatives are known to be more potent inhibitors 
of the enzyme).[11] The high efficacy of these compounds 
(although more active towards hTS) encourages the discovery of 
TbTS inhibitors. Nonetheless, the high similarity between the 
human and T. brucei ortholog (60%) and the identical amino acid 
composition of their active sites anticipate the difficulty in reaching 
selectivity. 
 
MINIREVIEW          
9 
 
 
Figure 11. Co-crystal structure of TbDHCH-41-NADP+ (a) and predicted binding mode of 43 (b) and 44 (c). The enzyme polypeptide is depicted as off-white ribbon, 
the interacting residues and the NADP+ nicotinamide ring are depicted as orange sticks, the inhibitors as cyan sticks.
Table 6. Activity of hTS inhibitors towards T. brucei. 
 
Compd TbTS Ki (nM) TbDHFR Ki (nM) T. brucei EC50 (μM) 
NTX 39.4 348 33.8 
RTX 215 93.1 0.038 
PMX 20500 290 0.020 
 
4.2. Methionine synthase (MS) 
Methionine synthase uses N5-CH3-THF, the major form of folates 
in human plasma, to convert hCys to Met, regenerating THF. This 
enzyme represents an important connection between folate and 
methionine metabolism. This last is linked to polyamine 
metabolism, a highly important target for the treatment of HAT.[38] 
It is tempting to assume that inhibitors of MS could perturb several 
biosynthetic pathways at the same time. 
5. Transporters 
Recently, three functional folate transporters (TbFT1-3) have 
been identified in T. brucei. These allow folate and analogues to 
cross cell membrane. The pABA-glutamyl moiety (present in 
folate and MTX) is essential for binding TbFT1-3. In the same 
study, evidences suggested the involvement of the mitochondrial 
carrier protein 2 (MCP2) in the import of folates to the 
mitochondrion, highlighting that one or more steps of the pathway 
happen in this organelle.[10] Considering the impact that these 
transporters might have on the availability and activity profile of 
the target molecules, it appears of primary importance to study 
possible interactions with folate transporters already in the early 
phases of drug discovery programs. Although not listed among 
essential transporters for the parasite,[39] they can indeed modify 
the distribution of the drugs in the cell and in its organelles, 
allowing or not the inhibitors to reach their targets. Moreover, as 
for other drugs,[5a, 5d] transporters might be involved in resistance 
mechanisms, a possibility that should be taken into account for 
the development of new successful therapies 
6. Conclusions and perspectives 
In the last years, researches have been focused on the inhibition 
of the reductive metabolism of folate presenting a massive 
quantity of data. Several remarkable results have been obtained, 
allowing a detailed knowledge of TbDHFR and TbPTR1 as targets. 
Much more has to be done in the study of the modification of THF 
into its two “charged” forms, N5,N10-CH2-THF and N10-CHO-THF. 
Although sometimes highly potent enzyme inhibitors have been 
obtained, the in vitro and in vivo activities of the compounds have 
never been good enough to be considered a valuable clinical 
candidate. Unfortunately, a discrepancy between the activities in 
biochemical assays and in vitro cell assays is often observed 
during the drug discovery of antiparasitic drugs. As mentioned 
above, it would be also of great interest to describe the 
transporters that could help the inhibitors to reach the intracellular 
environment and the early evaluation of the capabilities of the 
active molecules to cross the cell membrane through these 
systems would greatly aid in the pursuit of effective drugs. 
Another important aspect to take into account is that, in the 
literature, there are many sound research works performed 
following a phenotypic approach. This is a powerful direct 
approach, but sometimes it could be interesting to include a 
qualitative target deconvolution study, in particular when recurrent 
structures of classical antifolate drugs (e.g., pyrimidines) are 
present in the set of molecule under investigation. It is not indeed 
excluded that inhibitors might inhibit different enzymes involved in 
folate metabolism. 
With this minireview, we hope to have produced a useful resume 
of the data collected up to now and to recall the attention to the 
promising and fascinating field of antifolate drugs. 
b) c) a) 
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Targeting the folate pathway has been a valuable strategy for the treatment of different diseases and, in particular, antimicrobial 
infections. Despite the simple metabolism of folates in Trypanosoma brucei, no effective antifolate to treat its infections has been 
described so far. In this minireview, we analyze the folate pathway of this parasite, showing a selection of the most important results 
obtained to date in this research field. 
 
 
